Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Enliven Therapeutics Inc has a consensus price target of $32.5 based on the ratings of 5 analysts. The high is $37 issued by HC Wainwright & Co. on September 9, 2024. The low is $27 issued by Jefferies on March 29, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Baird, and Mizuho on September 9, 2024, June 11, 2024, and April 9, 2024, respectively. With an average price target of $34.33 between HC Wainwright & Co., Baird, and Mizuho, there's an implied 57.78% upside for Enliven Therapeutics Inc from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for Enliven Therapeutics (NASDAQ:ELVN) was reported by HC Wainwright & Co. on September 9, 2024. The analyst firm set a price target for $37.00 expecting ELVN to rise to within 12 months (a possible 70.04% upside). 3 analyst firms have reported ratings in the last year.
The latest analyst rating for Enliven Therapeutics (NASDAQ:ELVN) was provided by HC Wainwright & Co., and Enliven Therapeutics initiated their buy rating.
There is no last upgrade for Enliven Therapeutics
There is no last downgrade for Enliven Therapeutics.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Enliven Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Enliven Therapeutics was filed on September 9, 2024 so you should expect the next rating to be made available sometime around September 9, 2025.
While ratings are subjective and will change, the latest Enliven Therapeutics (ELVN) rating was a initiated with a price target of $0.00 to $37.00. The current price Enliven Therapeutics (ELVN) is trading at is $21.76, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.